Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model

Lian,Yuling; Zhao,Fangui; Wang,Wenjun

doi:10.3892/mmr.2020.10953

Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model

Authors:
- Yuling Lian
- Fangui Zhao
- Wenjun Wang
View Affiliations

Affiliations: Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, P.R. China
Published online on: January 20, 2020 https://doi.org/10.3892/mmr.2020.10953
Pages: 1461-1470
Copyright: © Lian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to elucidate the underlying mechanisms of Bao Gui capsule (BGC) against hyperandrogenism, insulin resistance and leptin resistance of PCOS. Letrozole was used to induce a PCOS model in rats, which were then randomly divided into four groups (n=9): Control, Model, high‑dose BGC (BGC‑H) and low‑dose BGC (BGC‑L) group. Serum levels of follicle‑stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), estradiol (E2), insulin, leptin, and interleukin (IL)‑1β, IL‑6 and tumor necrosis factor‑α (TNF‑α) in the hypothalamus were determined by ELISA. Protein levels of cytochrome P450c17α and cytochrome P450 aromatase (P450arom) in ovaries were determined by immunohistochemistry and western blot analysis. Additionally, the expression of GLUT4 in uterus and muscle tissue, and NF‑κB, IKKβ and SOCS3 mRNA levels in the hypothalamus were evaluated. BGC significantly reduced body weight gain and decreased serum levels of LH/FSH, T, log T/E2, insulin and leptin compared with the PCOS model rats. Furthermore, BGC markedly reduced the expression of P450c17α and significantly increased the expression of P450arom in ovaries, and increased the expression of GLUT4 in uterus and muscle tissues. BGC also effectively reduced the level of IL‑6 and TNF‑α, and the expression of IKKβ, NF‑κB and SOCS3 in the hypothalamus of PCOS model rats. These results suggest that BGC may effectively improve hyperandrogenism, insulin resistance, endometrial receptivity and the low‑grade chronic inflammation in the hypothalamus.

View Figures

View References

1	March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ and Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 25:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
2	Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ and Costello MF; Guideline Development Groups, : Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline. Med J Aust. 195:S65–S112. 2011. View Article : Google Scholar : PubMed/NCBI
3	Moran LJ, Misso ML, Wild RA and Norman RJ: Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update. 16:347–363. 2010. View Article : Google Scholar : PubMed/NCBI
4	Qin KN and Rosenfield RL: Role of cytochrome P450c17 in polycystic ovary syndrome. Mol Cell Endocrinol. 145:111–121. 1998. View Article : Google Scholar : PubMed/NCBI
5	Garvey WT, Maianu L, Hancock JA, Golichowski AM and Baron A: Gene-expression of GLUT4 in skeletal-muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 41:465–475. 1992. View Article : Google Scholar : PubMed/NCBI
6	Shepherd PR and Kahn BB: Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med. 341:248–257. 1999. View Article : Google Scholar : PubMed/NCBI
7	Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B, Maffei P, Martini C, Blandamura S, Sicolo N and Vettor R: Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab. 89:4089–4096. 2004. View Article : Google Scholar : PubMed/NCBI
8	Frolova AI and Moley KH: Glucose transporters in the uterus: An analysis of tissue distribution and proposed physiological roles. Reproduction. 142:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
9	Trayhurn P and Beattie JH: Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 60:329–339. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sainz N, Gonzalez-Navarro CJ, Martinez JA and Moreno-Aliaga MJ: Leptin signaling as a therapeutic target of obesity. Expert Opin Ther Targets. 19:893–909. 2015. View Article : Google Scholar : PubMed/NCBI
11	Pusalkar M, Meherji P, Gokral J, Savardekar L, Chinnaraj S and Maitra A: Obesity and polycystic ovary syndrome: Association with androgens, leptin and its genotypes. Gynecol Endocrinol. 26:874–882. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lian Y, Zhao F and Wang W: Central leptin resistance and hypothalamic inflammation are involved in letrozole-induced polycystic ovary syndrome rats. Biochem Biophys Res Commun. 476:306–312. 2016. View Article : Google Scholar : PubMed/NCBI
13	Prelevic GM, Puzigaca Z and Balint-Peric LA: Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome. Ann N Y Acad Sci. 687:255–262. 1993. View Article : Google Scholar : PubMed/NCBI
14	Palomba S, Falbo A, Russo T, Orio F, Tolino A and Zullo F: Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): Relationship to the ovulatory response. Hum Reprod. 25:1005–1013. 2010. View Article : Google Scholar : PubMed/NCBI
15	Spritzer PM, Motta AB, Sir-Petermann T and Diamanti-Kandarakis E: Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol. 40:195–212. 2015.PubMed/NCBI
16	Raja-Khan N, Stener-Victorin E, Wu X and Legro RS: The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 301:E1–E10. 2011. View Article : Google Scholar : PubMed/NCBI
17	Zhou J and Qu F: Treating gynaecological disorders with traditional Chinese medicine: A review. Afr J Tradit Complement Altern Med. 6:494–517. 2009.PubMed/NCBI
18	Zhou LR and Yu J: Clinical observation on treatment of hyperinsulinemia and hyperandrogenism anovulatory patient with replenishing kidney-yin drugs. Zhongguo Zhong Xi Yi Jie He Za Zhi. 16:515–518. 1996.(In Chinese). PubMed/NCBI
19	Hou J, Yu J and Wei M: Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula ‘tiangui fang’. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:589–592. 2000.(In Chinese). PubMed/NCBI
20	Sun F and Yu J: Effect of tiangui recipe on serum leptin and pituitary gonadotropin in androgen-sterilized rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 19:350–352. 1999.(In Chinese). PubMed/NCBI
21	Yu J and Cheng HY: Experimental studies on the relation of the kidney and reproduction. Zhong Xi Yi Jie He Za Zhi. 9548–551. (517)1989.(In Chinese). PubMed/NCBI
22	Kuek S, Wang WJ and Gui SQ: Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: A randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 9:965–972. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhang XJ, Chen YQ, Gui SQ, Qian QH and Guo SX: Clinical observation on Tiangui Capsule for 110 cases of polycystic ovary syndrome. J Trad Chin Med. 55:1835–1840. 2014.(In Chinese).
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Fan YS, Sasi R, Lee C, Winter JS, Waterman MR and Lin CC: Localization of the human CYP17 gene (cytochrome P450(17alpha) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics. 14:1110–1111. 1992. View Article : Google Scholar : PubMed/NCBI
26	McNatty KP, Makris A, DeGrazia C, Osathanondh R and Ryan KJ: The production of progesterone, androgens, and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab. 49:687–699. 1979. View Article : Google Scholar : PubMed/NCBI
27	Moon YS, Tsang BK, Simpson C and Armstrong DT: 17beta-Estradiol biosynthesis in cultured granulosa and thecal cells of human ovarian follicles: Stimulation by follicle-stimulating hormone. J Clin Endocrinol Metab. 47:263–267. 1978. View Article : Google Scholar : PubMed/NCBI
28	Harlow CR, Bradshaw AC, Rae MT, Shearer KD and Hillier SG: Oestrogen formation and connective tissue growth factor expression in rat granulosa cells. J Endocrinol. 192:41–52. 2007. View Article : Google Scholar : PubMed/NCBI
29	Schulte MM, Tsai JH and Moley KH: Obesity and PCOS: The effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod Sci. 22:6–14. 2015. View Article : Google Scholar : PubMed/NCBI
30	Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J and Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 11:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
31	Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ and Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI
32	Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M and Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science. 293:1673–1677. 2001. View Article : Google Scholar : PubMed/NCBI
33	Zhang X, Zhang G, Zhang H, Karin M, Bai H and Cai D: Hypothalamic IKKbeta/NF-kappaB and er stress link overnutrition to energy imbalance and obesity. Cell. 135:61–73. 2008. View Article : Google Scholar : PubMed/NCBI
34	Benzler J, Ganjam GK, Pretz D, Oelkrug R, Koch CE, Legler K, Stöhr S, Culmsee C, Williams LM and Tups A: Central inhibition of IKKβ/NF-κB signaling attenuates high-fat diet-induced obesity and glucose intolerance. Diabetes. 64:2015–2027. 2015. View Article : Google Scholar : PubMed/NCBI
35	Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H and Yoshimura A: Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med. 10:739–743. 2004. View Article : Google Scholar : PubMed/NCBI
36	Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C and Flier JS: Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med. 10:734–738. 2004. View Article : Google Scholar : PubMed/NCBI